I think CYP is a great pick to recover.
It's holding up well and proves that compared to the likes of FTT, POH, IIL etc, it's not a 1 hit wonder...but a tech platform in a very very new cell area.
Still 6 bags + on RTO.
Fuji likely to take less than the new timeline, and that's just a small indication. I think the whole Fuji thing has clouded the other targets, like CLI, OA, Asthma and wound care all progressing to Phase 2....so is just an opportunity ST
i still hold plenty (in T40)
- Forums
- Commodities
- Biotech Analysts $4M pa
Biotech Analysts $4M pa, page-43
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Featured News
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online